Smith & Nephew Describes Impact of Chip Scarcities on Medical Devices

Smith & Nephew’s CEO, Deepak Nath, has described how the medical device market is having to resort to older model chips in order to fulfil regulation requirements. This is because they have not been acknowledged as a priority by chip manufacturers at a time when requests for semiconductor dependent products are surpassed by supply.

Smith & Nephew’s Q4 sales rose by 1.4% to $1.4 billion in the last fiscal year. During the same year, sales also increased by 4.7& to $5.2 billion.

Nath explained that the company “could have sold a lot more of our systems in sports, or in wound than we actually did. The demand for it was greater than our ability to actually produce.”

These scarcities resulted in “very, very significantly higher prices.”

Over the last few months, estimates from producers of these chips, for example Intel, AMD, and Qualcomm, have been drastically reduced as global chip scarcity gave way to a supply surplus in certain regions.

Suppliers look at who is ordering the highest quantity of these products and place the most importance on them. Therefore, a lot of medical device manufacturers who do not request as many are being put at the bottom of the priority list and are left with little choice but to continue using the chips that were employed when their products were initially cleared by legal bodies.

Shortly after the business revealed that that this year it is aiming for a revenue upsurge of 5-6%, its London stocks increased by 4.2%.

By 2025, Smith & Nephew has set an objective to increase their profit margin to a minimum of 20%. Adjusted earnings per share for Q4 were 82 cents, which exceeded expert predictions of 78 cents.

Pre-tax profit for 2022 decreased by 60% to $235 million as the business struggled with rising expenses for staff, resources, and parts.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.